Management of brain metastases in non-small cell lung cancer

Cancer and Chemotherapy Reviews

Volumn 7, Issue 1, 2012, Pages 30-37

  Houdu, Marie Chaubet ^a   Besse, Benjamin ^a   Le Pechoux, Cećile ^a   Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Brain metastases; Chemotherapy; EGFR; Non small cell lung cancer; Radiosurgery; Tyrosine kinase inhibitor; Whole brain radiotherapy

Indexed keywords

ANTICONVULSIVE AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; FOTEMUSTINE; GADOLINIUM TEXAPHYRIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LAPATINIB; NAVELBINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM; STEROID; TEMOZOLOMIDE; TENIPOSIDE;

ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYBERKNIFE; DRUG SAFETY; EDEMA; GAMMA KNIFE RADIOSURGERY; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEEDLE BIOPSY; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIATION DOSE; RADIOGRAPHY; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; SEIZURE; SKIN TOXICITY; SKULL IRRADIATION; TREATMENT OUTCOME; TUMOR CELL;

EID: 84860236442     PISSN: 1885740X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Dunant A, Pignon J-P. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial. Clin Cancer Res. 2005;11:5017-21s.
2. Mamon HJ, Yeap BY, Jänne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005;23:1530-7.
3. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745-51. (Pubitemid 27181303)
4. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70:510-14.
5. Nieder C, Bremnes RM, Andratschke NH. Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol. 2009;4:1337-41. *A comparison of different prognosis scores in BM from NSCLC.
6. Lock M, Chow E, Pond GR, et al. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? Clin Oncol (R Coll Radiol). 2004;16:332-8. (Pubitemid 38967253)
7. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476-84. (Pubitemid 29372887)
8. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009;27:78-84.
9. Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1991;21:637-43.
10. Umsawasdi T, Valdivieso M, Chen T, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neuro Oncol. 1984;2:253-9. (Pubitemid 14046716)
11. Cox JD, Stanley K, Petrovich Z, Paig C, Yesner R. Cranial irradiation in cancer of the lung of all cell types. JAMA. 1981;245:469-72. (Pubitemid 11174712)
12. Miller T, Crowley J, Mira J. A randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. Cancer Ther. 1998;229-36.
13. Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol. 2011;29:272-8.*Latest study of PCI in NSCLC.
14. Pöttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol. 2007;25:4987-92. (Pubitemid 350220432)
15. Forsyth PA, Weaver S, Fulton D, et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. 2003;30:106-12. (Pubitemid 36717992)
16. Gaspar LE, Mehta MP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:17-32. *Complete review of the role of WBRT in BM.
17. De Angelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-96. (Pubitemid 19150153)
18. Mehta MP, Rodrigus P, Terhaard CHJ, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003;21:2529-36. (Pubitemid 46606335)
19. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys. 2009;73:1069-76.
20. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322:494-500. (Pubitemid 20067825)
21. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33:583-90. (Pubitemid 23161878)
22. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78:1470-6. (Pubitemid 26317868)
23. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-72.*Largest study showing the efficacy of RS. (Pubitemid 38670323)
24. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427-34. (Pubitemid 29408559)
25. Deeken JF, Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res. 2007;13:1663-74. (Pubitemid 46952931)
26. Stewart DJ, Molepo JM, Green RM, et al. Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer. 1995;71:598-604.
27. Stewart DJ, Molepo JM, Eapen L, et al. Cisplatin and radiation in the treatment of tumors of the central nervous system: pharmacological considerations and results of early studies. Int J Radiat Oncol Biol Phys. 1994;28:531-42. (Pubitemid 24020543)
28. Stewart DJ, Erasmus JJ. Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor. J Thorac Oncol. 2011;6:1149-51.
29. Ceresoli GL, Cappuzzo F, Gregorc V, Bartolini S, Crinò L, Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol. 2004;15:1042-7. (Pubitemid 39089780)
30. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50. (Pubitemid 44917502)
31. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr U-P. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res. 2010;16:269-78.*Large retrospective study examining the risk of blood hemorrhage with bevacizumab in BM.
32. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol. 2009;27:5255-61.*Prospective study of the use of bevacizumab in NSCLC traited BM.
33. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:45-68.
34. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96:33-43.
35. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol. 2001;12:59-67.*One of the only studies of WBRT or chemotherapy first in BM NSCLC. (Pubitemid 32162449)
36. Lee DH, Han J-Y, Kim HT, et al. Primary chemotherapy for newly diagnosed non-small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer. 2008;113:143-9. (Pubitemid 351976395)
37. Bachelot TD, Romieu G, Campone V. An FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol. 2011;(suppl) [abstract 509].
38. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15:1452-9.
39. Wu C, Li L-Y, Wang M-Z, et al. [Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis]. Zhonghua Zhong Liu Za Zhi. 2007;29:943-5.
40. Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer. 2001;32:129-36. (Pubitemid 32372605)
41. Kepka L, Cieslak E, Bujko K, Fijuth J, Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol. 2005;44:389-98. (Pubitemid 41021044)
42. Gülbas H, Erkal HS, Serin M. The use of recursive partitioning analysis grouping in patients with brain metastases from non-small-cell lung cancer. Jpn J Clin Oncol. 2006;36:193-6. (Pubitemid 43997317)
43. Rades D, Schild SE, Lohynska R, Veninga T, Stalpers LJA, Dunst J. Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients. Cancer. 2007;110:1077-82. (Pubitemid 47312874)
44. Videtic GMM, Reddy CA, Chao ST, et al. Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification. Int J Radiat Oncol Biol Phys. 2009;75:1141-7.
45. Agarwal JP, Wadasadawala T, Munshi A, et al. Validation of recursive partitioning analysis classification in patients with brain metastases from non-small cell lung cancer treated with short-course accelerated radiotherapy. Clin Oncol (R Coll Radiol). 2010;22:837-43.
46. Cotto C, Berille J, Souquet PJ, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer. 1996;32A:69-71.
47. Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology. 1996;53:210-13. (Pubitemid 26131944)
48. Minotti V, Crinò L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer. 1998;20:93-8. (Pubitemid 28345190)
49. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer. 1999;85:1599-605. (Pubitemid 29152834)
50. Fujita A, Fukuoka S, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer. Oncology. 2000;59:291-5.
51. Bernardo G, Cuzzoni Q, Strada MR, et al. First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study. Cancer Invest. 2002;20:293-302. (Pubitemid 34496561)
52. Cortes J, Rodriguez J, Aramendia JM, et al. Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer. Oncology. 2003;64:28-35. (Pubitemid 35477952)
53. Galetta D, Gebbia V, Silvestris N, et al. Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: a multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603). Lung Cancer. 2011;72:59-63.
54. Barlesi F, Gervais R, Lena H, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22:2466-70.
55. Chiu C-H, Tsai C-M, Chen Y-M, Chiang S-C, Liou J-L, Perng R-P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer. 2005;47:129-38. (Pubitemid 39643250)
56. Kim J-E, Lee DH, Choi Y, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer. 2009;65:351-4.